RNA Targeted Therapeutics Market Size
Market Size in USD Bn
CAGR35.4%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 35.4% |
| Market Concentration | High |
| Major Players | Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR Therapeutics, Eloxx Pharmaceuticals and Among Others |
please let us know !
RNA Targeted Therapeutics Market Analysis
The RNA targeted therapeutics market is estimated to be valued at USD 1.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 35.4% from 2025 to 2032.
The market is witnessing positive trends owing to rising prevalence of target medical conditions and increasing number of RNA therapeutics under clinical trials. There has been a considerable increase in research and development activities for RNA therapeutics over the past decade. Many biopharma companies are actively working on RNA interference technologies to develop treatment for cancer, genetic diseases, and infectious diseases. Recent regulatory approvals and successful commercialization of few RNA therapeutics have boosted confidence in this platform. If upcoming clinical trial results are positive, it may lead to approval and commercialization of more RNA drugs in the near future. This will upsurge demand and drive higher market revenues during the forecast period.